“…The BBB is also positive, signifying that these compounds could enter the blood-brain barrier. CYPs play a vital role in the metabolism of drugs by catalyzing their biotransformation which is responsible for their degradation and excretion [ 52 ]; it is necessary to identify CYP-inhibiting properties during development of a new drug. Most of the analogues resulting from drug-likeness have low CYP450 inhibitory properties, except HCQ2, HCQ3, and CQ14 to CQ18 and CQ20 to CQ27.…”